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Abstract
Peripartum cardiomyopathy (PPCM) is the most common cardiomyopathy in 
pregnancy. It is potentially life-threatening. It is, diagnosed in women without a 
history of heart disease 1 month before delivery or within 5 months. It is marked by 
heart failure and left ventricular dyshfunction. The evolution is favorable. LV func-
tion improves within 6 months in the majority of patients, but long-lasting mortal-
ity and morbidity are not infrequent. Recent work suggests the critical toxic role for 
late-gestational hormones on the maternal vasculature and the genetic underpin-
nings of PPCM. Complications include different types of supraventricular and 
ventricular arrhythmias, heart failure and ischemic stroke. The brain natriuretic 
peptide (BNP) can be used to risk stratify women for adverse events. Management 
of peripartum cardiomyopathy is based on treatment of heart failure. The addition 
of bromocriptine seemed to improve LVEF. Close monitoring of pregnant women 
with cardiomyopathy by multidisciplinary team is recommended.
Keywords: pregnancy, cardiomyopathy, heart failure
1. Introduction
In the 1800s, heart failure associated with pregnancy and the peripartum period 
was recognized for the first time by Virchow and others [1]. However, the term 
peripartum cardiomyopathy (PPCM) was not introduced until 1971 by Demakis 
and Rahimtoola [2]. Those authors, specifically defined the syndrome as occurring 
in the peripartum period.
In 2010, the European Society of Cardiology provided operational definition of 
PPCM as cardiomyopathy with reduced EF, usually <45%, presenting toward the 
end of pregnancy or in the months after delivery in a woman without previously 
known structural heart disease [3]. Cardiac imaging before clinical presentation is 
almost never available in these young women, therefore, the absence of preexisting 
heart disease is usually only presumed [4].
Why this interest in peripartum cardiomyopathy? It is both the most common 
cardiomyopathy in pregnancy and the most common non-obstetric cause of  
maternal death.
The timing of PPCM is not certain. Most cases occur in the first weeks after 
delivery [2].
However, it can also present well before and up to months after delivery.
These uncertainties make the definition of this disease imprecise and reflects 
our still incomplete understanding of PPCM.
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Many potential causes have been proposed, including autoimmunity, viral 
myocarditis, nutritional deficiencies, and hemodynamic stresses [5]. Most recently, 
a role for vascular dysfunction, hormonal insults, and underlying genetics has been 
suggested. But, the cause of PPCM remains unknown.
Clinical recognition is integral to the management of this disease, because there 
must be careful exclusion of alternative etiologies. Specific diagnostic or prognostic 
tests are lacking.
Management of peripartum cardiomyopathy is based on standard heart failure 
therapy. The addition of bromocriptine seemed to improve LVEF.
2. Epidemiology
The reported incidence of PPCM varies between 1:100 and 1:20 000 deliveries 
worldwide and between races within countries. Accurate data are lacking because of 
the paucity of population-based registries.
The Kaiser Permanente Health system, which is the USA’s largest non-profit health 
plan including 9.9 million members, provided data that identified pregnant women 
with heart failure from 2003 to 2014 [6]. Among these women, PPCM occurred in 333 
(68.2%). An analysis of 64 million discharge US hospital records from 1000 hospitals 
in 47 states identified 34 219 cases of PPCM, with an incidence of 1 in 968 births [7].
A higher incidence of disease is found among African-American woman, who 
are 3-to 16-fold more likely to be diagnosed with PPCM [8, 9]. The incidence of 
PPCM in Africa and Asia suggest an incidence of ≈1 in 1000 live births [6]. Women 
of African descent are more likely to develop PPCM.
However, there are some striking hot spots of PPCM, the cause of which remains 
unclear. In northern Nigeria, the incidence of PPCM may be as much as 1 in 100 
live births [10]. In Haiti, the incidence of PPCM has been reported as high as 1 
in 300 live births [11] possibly related to racial background, a high prevalence of 
preeclampsia or nutritional deficiencies.
An increasing trend of PPCM has been reported in many studies. For example, 
from 8.5 to 11.8 per 10 000 live births between 2004 and 2011 [7] and from 2.3 to 
4.5 per 10 000 live births between 1990 and 2002 [12]. This increasing incidence 
is probably related to the increased recognition and diagnosis of disease, rising 
maternal age and multifetal pregnancies, or changing demographics [12, 13].
As the incidence of PPCM increases, the mortality increases as well. In a 
Californian study of maternal cardiovascular deaths between 2002 and 2006, 
PPCM was the leading cause (23%) [14].
3. Predisposing factors
Risk factors for PPCM are not understood. Studies have shown that increasing 
age, African ethnicity, pre-eclampsia, multiparity, malnutrition and traditional risk 
factors for cardiovascular disease, such as hypertension, diabetes and smoking, are 
associated with PPCM.
3.1 Age
The incidence of PPCM is associated with age. More than 50% of cases occur 
in women over 30 years of age [7, 8] with an odds ratio of 10 in a comparison of 
women less than 20 years of age [7].
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Although the disease can strike women of any age, most women in the United 
States are diagnosed in women older than 30 years [15].
3.2 Race
PPCM affects black women more often. A study in California noted an incidence 
of PPCM in blacks of 1 in 1421, nearly 3 times that in whites [8].
In a population study of cases in North Carolina in 2003, the incidence of PPCM 
in black women was 4 times that of white women (1,1087 versus 1,4266), and the 
fatality rate at 5-year follow-up was also 4 times as high (24% versus 6%) [16].
3.3 Preeclampsia and eclampsia
Preeclampsia strongly predispose to PPCM. However, it is important to realize 
that PPCM is not simply a manifestation of severe preeclampsia.
A meta-analysis of 22 studies covering 979 cases of PPCM showed an overall 
prevalence of preeclampsia of 22%, >4 times the 3–5% population prevalence 
[17]. The prevalence of preeclampsia in many of these studies may be under-
estimated because preeclampsia is often underreported and because the pres-
ence of preeclampsia is often used as an exclusion criterion from the diagnosis 
of PPCM.
PPCM is also frequently found in association with eclampsia, with an odds ratio 
of 12.9 in a California population study of 1888 patients with eclampsia [18].
It is important to realize that preeclampsia can also trigger pulmonary edema in 
the absence of PPCM. The cardiac toxicity caused by preeclampsia can be clini-
cally silent but can also present as pulmonary edema with preserved EF or as part 
of PPCM. A number of echocardiographic studies have shown that preeclampsia 
causes diastolic dysfunction even in the absence of clinical heart failure [19]. This 
diastolic dysfunction is independent from blood pressure elevations and can persist 
up to 1 year after delivery and resolution of preeclampsia [4].
The strong association between preeclampsia and PPCM suggests that they may 
share pathophysiological mechanisms. The suspicion for PPCM should never be 
lowered in the presence of preeclampsia.
3.4 Multiple gestations
Rate of twin births is generally higher in reports of PPCM than in the general 
population.
PPCM is frequently reported in cases of multigestational status. According to a 
meta-analysis, the average rate of twin gestations in cases of PPCM across 16 studies 
was 9% well above the average estimated prevalence of 3% [17, 20].
Although multiparity has traditionally been defined as a risk factor for PPCM, 
recent studies have shown that the majority of cases of PPCM in the US occur dur-
ing the first or second pregnancy [2, 15].
3.5 Hypertension
According to a meta-analysis covering 979 cases of PPCM, hypertensive disorder 
was present in 37% (range, 29–45%) of cases [17]. A study of US hospital discharge 
records in 6 states identified 535 patients with PPCM, of whom 46.9% had hyper-
tension (odds ratio, 13.4) [21].
We may say that hypertension strongly predispose to PPCM.
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3.6 Other factors
Substance abuse, anemia, asthma, diabetes mellitus, obesity, and malnutrition 
are other associated conditions that have been reported but less well substantiated.
4. Hemodynamic changes during normal pregnancy
4.1 Antepartum changes
During pregnancy, several hemodynamic changes occur [22]:
• Preload increases: Maternal blood volume begins to increase at 6 weeks’ gesta-
tion. By the second trimester, maternal blood volume increases to 50% above 
baseline. This effect leads to increased preload and left ventricular end-  
diastolic volume.
• Afterload decreases: As the uterine circulation increases during the first trimes-
ter, the systemic vascular resistance falls. There is further peripheral vasodila-
tation that occurs, likely from decreased vascular responsiveness to angiotensin 
and norepinephrine. These cumulative changes result in a decrease in maternal 
blood pressure.
• Heart rate increases: The heart rate increases by 15–20% by the third trimester 
(secondary to increased sympathetic tone).
In normal pregnancy, cardiac output increases by 30–50% through increased 
stroke volume during the first two trimesters. During the second part of pregnancy, 
cardiac output increases through an increase in heart rate. These changes are 
illustrated in Figure 1.
Cardiac output varies by maternal position. When supine, the gravid uterus can 
compress the inferior vena cava and impede venous return to heart and the cardiac 
output can decrease by 25%.
Despite these dramatic hemodynamic alterations, intrinsic left ventricular 
contractility does not appear to change appreciably [24]. The cardiac atria and 
ventricles must, however, accommodate the pregnancy-induced hypervolemia. 
Figure 1. 
Changes in hemodynamic properties throughout pregnancy. (data derived from Robson et al. [23]).
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Consequently, normal pregnancy is associated with increased left ventricular mass 
[25, 26]. Such cardiac remodeling is a normal, physiologic response, and some, but 
not all, suggest these changes resolve by 3 months postpartum [27].
The increase in plasma volume during pregnancy is larger than the increase in 
red blood cells, which leads to physiological anemia. Systemic vascular resistance 
decreases at the end of the second trimester and then increases toward the end of 
pregnancy.
4.2 Labor and delivery
Marked fluctuations in cardiac output occur, during labor and delivery. Each 
uterine contraction can contribute up to 500 milliliters (ml) of maternal blood 
volume due to auto- transfusion of uterine blood [22].
Cardiac output can increase as much as 30% during the first stage of labor and 
up to 50% during the second stage due to maternal pushing [28]. Cardiac output is 
also augmented by the sympathetic surge induced by anxiety and pain. Immediately 
after delivery, the cardiac output can increase by 80% above pre-labor values due to 
auto-transfusion from the uterus during contractions and from the utero-placental 
circulation after relief of vena caval compression by the uterus. Blood loss during a 
normal delivery may be 500–1000 mL but is partly compensated by the increase in 
stroke volume.
Hemodynamic changes are fully reset after 6 months. During pregnancy and 
postpartum, patients remain in a hypercoagulable state.
5. Physiopathology
Until recently, the etiology and pathophysiology of peripartum cardiomyopathy 
have been elusive, not fully understood and likely multifactorial.
One of the oldest theories is that PPCM is simply a failed hemodynamic “stress 
test” of pregnancy. According to this, the cardiovascular changes during pregnancy 
we detailed before, ultimately lead to peripartum heart failure. We would expect 
then that PPCM will occur early in midpregnancy, as the maximal changes always 
start in this period. However, with very few exceptions, PPCM is a disease of late 
pregnancy and after the delivery. Thus, if peripartum cardiomyopathy were a failed 
stress test, it would occur much earlier and more often than it does [29].
Another old hypothesis suggested that PPCM is triggered by viral myocarditis. 
This observation came from findings that right-sided endomyocardial biopsies dis-
played evidence of inflammation. In a series of endomyocardial biopsies performed 
in 38 women from Niger (similar proportions of women with PPCM and controls), 
Inflammation was variably present in endomyocardial biopsies taken from women 
with the condition, however few patients met histologic criteria for myocarditis 
[30–32]. Cardiac magnetic resonance (CMR) imaging was performed in a cohort of 
40 women in the Investigations in Pregnancy-Associated Cardiomyopathy (IPAC), 
only one woman had findings potentially consistent with myocarditis [33].
Other potential causes for PPCM have also been proposed. Microchimerism, 
with fetus-derived cells that can persist in the immune-suppressed pregnant state 
and can lodge in the maternal heart, has been proposed as a trigger for autoimmu-
nity after delivery [34].
Deficiencies of iron and selenium have also been proposed. The current theory 
regarding the pathophysiology of peripartum cardiomyopathy suggest that it is 
genetically predisposed. As previously discussed, this is evidenced epidemiologi-
cally by geographic and racial variations. In a German registry, 15% of women 
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with PPCM had a family history of cardiac disease in a first-degree relative [35]. 
Genetic studies have supported the notion that genetics contribute to PPCM. 
Mutations in the TTNC1 and TTN genes that encode cardiac myoprotein troponin 
C and titin have been identified in women with PPCM [36]. The titin is a critical 
structural component of sarcomeres in cardiac and skeletal muscle. However, 
over 90% of individuals with TTN truncating variants do not develop PPCM, 
indicating that additional environmental, genetic, or epigenetic factors are at 
play [37].
A landmark 2007 article first introduced that PPCM is a vascular disease trig-
gered by the hormonal changes of late pregnancy. Although the idea was proposed 
in the past, experimental support for it was lacking. Recently, a 2 mice models and 
epidemiological data started supporting the notion that PPCM is in large part a 
vascular disease, triggered by the hormonal milieu of the peripartum [38, 39].
The first mouse lacked the cardioprotective STAT3 gene also accused of devel-
oping the peripartum cardiomyopathy. In this case, the oxidative stress led to 
cleavage of the nursing hormone, prolactin. The 16-kDa prolactin fragment had 
vasculotoxic and pro- apoptotic properties and vascular and myocardial  
dysfunction (Figure 2) [36].
Figure 2. 
Pathogenesis of peripartum cardiomyopathy: 1) genetic predisposition caused by mutations of various genes 
(STAT3, TTN, TTNC1) that regulate cardiomyocyte function causes secretion of cathepsin D (CathD), which 
cleaves pituitary prolactin (PRL) to form a 16-kDa fragment, vasoinhibin; 2) vasoinhibin acts on blood vessels 
to trigger apoptosis as well as microRNA-146a resulting in cardiomyocyte ischemia, metabolic insufficiency, 
and apoptosis. Simultaneously, the placenta, especially with the preeclampsia syndrome, secretes soluble 
fms-like tyrosine kinase 1 (sFlt-1), which neutralizes vascular endothelial growth factors A and B (VEGFA 
and VEGFB, respectively) that are critical for vascular health. MnSOD, mitochondrial antioxidant manganese 
superoxide dismutase; ROS, reactive oxygen species. (data from Arany and Elkayam [4]; Arany [40]. 
Illustrations created by Ceara Byrne, MS. Commented by Cunningham [29]).
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The second mouse had another cardiac-specific genetic deletion of prolifera-
tor-activated receptor gamma coactivator-1a (PGC-1a) leading to vasculotoxic-
ity by activation of the 16-kDa prolactin fragment and decreased expression of 
vascular endothelial growth factor (VEGF) [36]. VEGF is antagonized by the 
placental secretion of soluble Fms-like tyrosine kinase 1 (sFlt1) which is suf-
ficient to cause profound systolic dysfunction in mice lacking cardiac PGC-1 
alpha. This was incriminated in the genesis of PPCM and predicted worse 
outcomes [41].
6. Clinical presentation
Diagnosis of PPCM may be difficult: the symptoms of heart failure during 
pregnancy can mimic signs and symptoms that occur during normal pregnancy. 
The majority of women with PPCM are diagnosed after delivery, precisely in the 
first month postpartum [3]. Unfortunately, delays in diagnosis are associated with 
increased incidence of preventable complications and worse outcomes [16, 42, 43].
At the time of diagnosis, patients most commonly complain of signs and symp-
toms of congestive heart failure including dyspnea, orthopnea and paroxysmal 
nocturnal dyspnea. Other common symptoms include cough, palpitations, chest 
tightness, abdominal pain and pitting edema of the lower extremities. If chest pain 
is severe, the clinical picture can suggest a myocardial infarction or pulmonary 
embolism.
Women can have difficulty lying flat for the exam. Physical examination usually 
reveals signs of heart failure including tachypnea, tachycardia, elevated jugular 
venous pressure, third heart sound, systolic murmur of tricuspid or mitral regur-
gitation, pulmonary rales, and peripheral edema. Almost half women will have 
peripartum hypertension and, commonly, Preeclampsia [3, 18, 44]. A minority of 
patients will present with severe arrhythmias, cardiogenic shock and thromboem-
bolic complications.
7. Diagnostic testing
Initial diagnostic studies will often include an electrocardiogram (ECG), chest 
x-ray, bloodwork, and echocardiogram. The 12-lead electrocardiogram usually 
shows only sinus tachycardia with non-specific ST- and T-wave changes. A normal 
electrocardiogram does not rule out PPCM [45]. A chest x-ray is not obligatory for 
diagnosis but if it is obtained, fetal shielding must be used. The chest x-ray may 
show an increased cardiac silhouette with varying degrees of pulmonary conges-
tion, edema and pleural effusions.
Assessment of kidney, liver and thyroid function is recommended along with 
evaluation for anemia and sepsis. Proteinuria must also be quantified. Levels of 
brain natriuretic peptide (BNP) and N-terminal pro-BNP, are not change signifi-
cantly during normal pregnancy [46], they can be mildly elevated in the setting of 
pre-eclampsia, but they are usually markedly elevated in PPCM [47].
Echocardiography is the gold standard for confirmation of diagnosis and must 
be obtained as soon as possible. It should be performed in any suspected case 
of PPCM as the LVEF is typically <45% [3]. It will show global reduction in LV 
systolic function with various degrees of LV dilatation. In addition to that, it may 
demonstrate right ventricular dilatation and/or dysfunction, functional mitral 
and/or tricuspid regurgitation, pulmonary hypertension, and left atrial or biatrial 
enlargement. Intracardiac thrombus may occur [48, 49], and the LV apex should be 
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clearly visualized. In the European worldwide registry of 411 patients, right ven-
tricular function was severely abnormal in 10%, normal in half, mildly abnormal in 
approximately 35%, and [50]. Hibbard et al. proposed stringent criteria to diagnose 
peripartum cardiomyopathy [51].
Cardiac magnetic resonance imaging (MRI) provides accurate ejection fraction 
and chamber measurements when the echocardiogram is inadequate. However, the 
use of MRI for diagnosis of PPCM is not routine practice as gadolinium should be 
avoided unless it is considered absolutely essential [52].
There is no role for routine endomyocardial biopsy. The endomyocardial biopsy 
can only be indicated in the woman for whom there is consideration for heart 
transplantation.
A summary done by Cunningham of the complete evaluation recommendations 
are shown in Figure 3.
8. Differential diagnosis
PPCM is a diagnosis of exclusion. The differential diagnosis includes common 
causes of pulmonary edema and cardiac failure. To avoid over diagnosis, careful 
attention to possible pre-existing heart disease including valvular disease and 
cardiomyopathies is crucial.
Sepsis syndrome causes endothelial inflammation and can result in myocardial 
dysfunction from sepsis-induced cardiomyopathy.
Pulmonary causes such as pneumonia facilitated by the immune tolerance dur-
ing pregnancy or pulmonary embolism resulting from the hypercoagulable peripar-
tum period might mimic a PPCM as well.
Figure 3. 
Evaluation of the woman with suspected peripartum cardiomyopathy. CBC, complete blood count; BMP, 
basic metabolic panel; LFT, liver function test; BNP, brain natriuretic peptide; LVEF, left ventricular ejection 
fraction; LVEDD, left ventricular end-diastolic diameter. (Cunningham [29]).
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Severe preeclampsia can cause pulmonary edema from a capillary– endothelial 
leak and decreased plasma oncotic pressure, and multifetal gestation and certain 
tocolytic agents increase this vulnerability. However, PPCM is only diagnosed in the 






Echocardiogram may show classic apical ballooning
Familial 
cardiomyopathy
Family history, genetic testing
Pre-existing 
cardiomyopathy




Ask about symptoms of HF that occurred after a prior pregnancy
Pre-eclampsia Preserved systolic function on echocardiogram
Hypertrophic 
cardiomyopathy
Left ventricular hypertrophy, LVOT obstruction, preserved systolic function, 
genetic testing




Consider with family history, genetic testing, echocardiographic findings
Left ventricular 
noncompaction
Echocardiographic and CMR findings
Chemotherapy-related 
cardiomyopathy
History of chemotherapy, particularly doxorubicin
Valvular heart disease Echocardiographic findings; congenital aortic stenosis; mitral stenosis from 
rheumatic heart disease in endemic country. Patients with PPCM may also have 
valve disease, i.e., mitral regurgitation
Congenital heart 
disease




Consider if specific underlying rhythm abnormality. Note that sinus tachycardia 
may be secondary to heart failure during pregnancy
Hypertensive heart 
disease
Left ventricular hypertrophy; less common in young people unless very 
longstanding history of hypertension
Ischemic heart disease Cardiovascular risk factors; angina; prior CAD; consider SCAD and MINOCA 
diagnoses
Cardiomyopathy 
related to other 
systemic medical 
diseases
Consider in the appropriate context, i.e., systemic lupus erythematosus, 
antiphospholipid syndrome, hemochromatosis
Cardiomyopathy 
related to other acute 
conditions
May consider if patient has other conditions such as sepsis, treatment in intensive 
care unit, post-respiratory arrest
Pulmonary embolism Dyspnea, tachycardia with preserved LVEF
CAD, coronary artery disease; CMR, cardiac magnetic resonance imaging; HF, heart failure; LVEF, left ventricular 
ejection fraction; LVOT, left ventricular outflow tract; MINOCA, myocardial infarction in non-obstructive coronary 
arteries; PPCM, peripartum cardiomyopathy; SCAD, spontaneous coronary artery dissection.
Table 1. 
Differential diagnosis for heart failure during pregnancy.
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Other much less common causes of peripartum heart failure include thyrotoxi-
cosis, lupus erythematosus, myocardial infarction and Takotsubo cardiomyopathy. 
Echocardiography is sufficient to differentiate from these causes.
Potential causes of pregnancy-related HF are listed in Table 1 [36].
9. Treatment
9.1 Initial management
Patients with PPCM presenting with symptoms of acute severe heart failure 
require prompt treatment in an intensive care unit. Intravenous diuretics should be 
given to patients having pulmonary congestion and volume overload. The caution is 
required if volume control used before delivery to avoid hypotension and impaired 
uterine perfusion. For rapid diagnosis and decision-making, a pre-specified manage-
ment algorithm and expert interdisciplinary team are crucial (Figures 3–5) [53, 54].
9.2 Chronic heart failure management
In postpartum, Angiotensin-converting enzyme inhibitors or angiotensin 
receptor blockers can be used. The Angiotensin-converting enzyme inhibitors or 
angiotensin receptor blockers are contraindicated before delivery, a combination of 
hydralazine and organic nitrates can be used instead during pregnancy.
During pregnancy, β-Blockade should be considered. to avoid promoting uterine 
activity, β-1–selective agents can be preferable. Digoxin may be safely used during 
pregnancy, but its role is currently being debated [55, 56].
9.3 Bromocriptine and cessation of breastfeeding
There’s an increase of Serum levels of a fragment of prolactin, called 16 kDa pro-
lactin during the puerperal period. In PPCM patients, the 16 kDa prolactin fragment 
is overexpressed and is thought to initiate and perpetrate excessive oxidative stress 
through reactive oxygen species, which then induces apoptosis via ischemia–reperfusion 
and hypoxia-reoxygenation mechanisms. This increase of 16 kDa prolactin culminates 
in myocardial dysfunction and symptomatic heart failure [57, 58]. Dopaminergic inhibi-
tion of prolactin secretion achieved with bromocriptine, is thought to thwart prolactin’s 
deleterious effects on cardiac function [41].
The addition of bromocriptine to standard heart failure therapy PPCM patients 
appeared to result in significantly greater improvements in NYHA functional class, 
LV systolic and diastolic function, degree of functional mitral regurgitation, and 
low morbidity and mortality in PPCM patients than seen with standard therapy 
alone [35, 59–62].
Moreover, although bromocriptine stopped lactation in the PPCM patients, the 
survival and growth of those infants were normal [60].
Bromocriptine can be prescribed in women with symptoms of congestive heart 
failure, no other identifiable cause for heart failure finded, that developed in the 
last month of pregnancy or during the first month postpartum, having LVEF failure 
<35% by transthoracic echocardiography.
According to the guidelines of European Society of Cardiology, the use of 
Bromocriptine (2.5 mg once daily) for at least 1 week may be considered in uncom-
plicated cases, while prolonged treatment (2.5 mg twice daily for 2 weeks, then 
2.5 mg once daily for 6 weeks) may be considered in patients with EF <25% and/or 
cardiogenic shock [63].
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Figure 5. 
Management of acute heart failure during/after pregnancy (modified from Bauersachs et al. [53]). A diuretics 
have to be used with caution due to potential reduction in placental blood flow. ACE-I, angiotensin-converting 
enzyme inhibitor; AHF, acute heart failure; ARB, angiotensin receptor blocker; ECG, electrocardiogram; 
HF, heart failure; HR, heart rate; LVEF, left ventricular ejection fraction; MCS, mechanical circulatory 
support; MR, mineralocorticoid receptor; NIV, non-invasive ventilation; PDA, Peridural analgesia; PPCM, 
peripartum cardiomyopathy; RR, respiratory rate; SBP, systolic blood pressure; ScvO2, central venous oxygen 
saturation; SpO2, peripheral oxygen saturation; WCD, wearable cardioverter-defibrillator.
Figure 4. 
Management of acute heart failure during pregnancy: Rapid interdisciplinary workup and treatment of 
mother and foetus (modified from Bauersachs et al. [53]). AHF, acute heart failure; HF, heart failure.
Cardiomyopathy - Disease of the Heart Muscle
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The bromocriptine should be not prescribed in women with systolic blood pres-
sure > 160 or < 95 mm Hg or diastolic >105 mm Hg; clinical conditions other than 
cardiomyopathy that could increase plasma levels of inflammatory markers such as 
sepsis, autoimmune disease, or HIV positivity; significant liver disease (defined as 
liver transaminase levels>2 times the upper limit of normal); history of peptic ulcer 
disease; history of psychiatric disorders; impaired renal function (defined as urea 
and/or creatinine >1.5 times the upper limit of normal [60].
Bromocriptine should not be used in the patient using triptans (for example, 
for the treatment of migraines), because of theoretical risks of serotoninergic 
syndrome or prolonged vasospastic reactions.
All patients receiving bromocriptine must receive standard heart failure therapy 
with at least prophylactic anticoagulation.
9.4 Thromboembolism and anticoagulation
Thromboembolic risk is higher in PPCM than other forms of cardiomyopathy 
[13]. The peripartum period is a hypercoagulable state [64], likely an evolutionary 
adaptation to minimize postpartum hemorrhaging. In patients with an LVEF <35%, 
the anticoagulation must be considered [65], at least during pregnancy and the first 
2 months postpartum. Heparin and unfractionated heparin are safe during preg-
nancy, and the unfractionated heparin is preferred because of its shorter half-life.
9.5 Arrhythmias and antiarrhythmic therapies
Beta-blockers and non-vasoselective calcium-channel blockers can be used safely 
for rate control of tachyarrhythmias. For PPCM patients, there are no guidelines for 
implantation of an implantable cardiac defibrillator (ICD). However, sudden cardiac 
death has been reported in PPCM patients with decreased LVEF in both the acute and 
chronic stages of this disease, as well as in those whose LVEF has completely normal-
ized, indicating that the risk of sudden cardiac death may persist well into recovery. It 
might be reasonable to consider ICD in patients with EF <30% with sustained ventric-
ular arrhythmias or history of survival after cardiac arrest, but this decision should be 
carefully weighed against the evidence that LV function improves within 6 months in 
the majority of patients. A suitable alternative is wearable cardioverter-defibrillator 
devices for patients with LVEF ≤35% to prevent sudden cardiac death [66, 67].
But it would be reasonable to consider ICD implantation in patients with persis-
tent NYHA class III or IV symptoms despite optimal medical therapy for 6 months 
and whose LVEF remains <30%.
9.6 Cardiac assist devices
Temporary circulatory support with inotropes, intra-aortic balloon pumps, LV 
and biventricular assist devices, and extracorporeal membrane oxygenation must be 
considered in patients who clinically deteriorate, despite optimal medical treatment, 
either as a bridge to recovery or transplantation [68]. As that LV function improves 
within 6 months in the majority of patients, the decision to refer the patient for 
cardiac transplantation should not be made too early. Results after transplantation in 
patients with PPCM are comparable to patients transplanted for other etiologies.
9.7 Obstetric management
Excessive volume depletion and angiotensin-converting enzyme inhibitors 
should be avoided. No published data exist to indicate that elective caesarian 
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delivery or early delivery can ameliorate PPCM or improve fetal prognosis. Apgar 
scores, mean birth weight and size, are lower in neonates born to women with 
PPCM, likely reflecting earlier gestational age at delivery [69]. Timing and mode 
of delivery must therefore be made by a team of obstetricians and cardiologists. 
Early delivery needs should be reserved for cases of impending peril to mother or 
fetus [70].
9.8 Subsequent pregnancies
Several studies highlighted the higher incidence of PPCM in women with high 
parity [11, 71, 72]. Increased morbidity and mortality is observed during subse-
quent pregnancies, especially in women with persistent left ventricular dysfunction 
after the first pregnancy [62–73]. Early contraception should be given in PPCM 
women [74].
10. Prognosis
The evolution is favorable. LV function improves within 6 months in the major-
ity of patients and will remain stable under drug treatment. The decision to refer 
the patient for cardiac transplantation estimated at 1–2% [12]. Prognosis of PPCM 
is better than the prognosis of other forms of dilated cardiomyopathy [75].
Mortality to 12 months is 4–14% [76, 77]. the addition of bromocriptine to stan-
dard heart failure therapy appeared to improve LVEF. A trial adding the prolactin 
blocker bromocriptine with standard therapy for heart failure reported an excellent 
6-month follow-up outcome in severely diseased patients having over 60% full 
recovery and 0%, heart transplantation, use of assist device and mortality [60].
Mortality between 2 and 5 years, ranging from 0 to 6% in American and French 
women [48–79], to 15–30% in women from Brazil, [80], China, [81] South Africa, 
[82] Turkey, [83–85] and the Philippines [86].
In USA the mortality ranging from 7 to 16% at between 7 and 8.6 years [16, 75, 77], 
the mortality was 23% at 6.1 years in India [87]. In Malaysia the mortality was 8.3% at 
6.4 years [88].
When myocardial recovery occurs in PPCM, There are no recommendations to 
determine the time of long-term treatment.
11. Conclusion
Management of peripartum cardiomyopathy is largely limited to the same 
neurohormonal antagonists used in other forms of cardiomyopathy, the addition of 
bromocriptine to standard heart failure therapy seemed to improve LVEF. LV func-
tion improves within 6 months in the majority of patients having optimal medical 
therapy. Whatever the evolution, long-term follow-up is essential. Early contracep-
tion should be given in PPCM women.
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